曲氟尿苷/替吡嘧啶治疗既往接受或未接受氟尿嘧啶类药物的转移性乳腺癌的II期研究
这项单臂II期研究纳入74例转移性乳腺癌患者,分既往暴露(A组42例)与未暴露(B组32例)氟尿嘧啶类两队列,均接受曲氟尿苷/替吡嘧啶治疗。A组中位无进展生存期5.7个月,B组9.4个月;客观缓解率分别为19.5%与16.1%,6个月临床获益率分别为56.1%与61.3%。安全性特征与已知毒性一致,毒性可通过剂量调整控制。
要点
- A组中位PFS 5.7个月,B组9.4个月。
- A组ORR 19.5%,B组ORR 16.1%。
- A组6个月临床获益率56.1%,B组61.3%。
核心结论
- 曲氟尿苷/替吡嘧啶显示出有前景的抗肿瘤活性,毒性可控,是转移性乳腺癌患者临床上可行的选择。
研究设计与样本
- 单臂II期研究,先进行剂量确认导入期,随后设两个平行队列:既往暴露氟尿嘧啶类(A组)与未暴露(B组),均接受曲氟尿苷/替吡嘧啶治疗。
- 共入组74例转移性乳腺癌患者(A组42例,B组32例),全部可评估毒性和生存,72例可评估疗效。
- 主要终点为无进展生存期,次要终点包括客观缓解率、安全性和耐受性。
主要发现
- A组中位无进展生存期5.7个月(95%CI 3.8-8.3),B组9.4个月(95%CI 5.5-14.0)。
- A组客观缓解率19.5%(95%CI 8.8-34.9),B组16.1%(95%CI 5.5-33.7)。
- A组6个月临床获益率56.1%(95%CI 39.7-71.5),B组61.3%(95%CI 42.2-78.2)。
- 安全性特征与曲氟尿苷/替吡嘧啶已知毒性一致,包括中性粒细胞减少、疲乏、恶心和厌食,通过剂量调整得到控制。
关键数值与推荐
- A组中位无进展生存期5.7个月(95%CI 3.8-8.3),B组9.4个月(95%CI 5.5-14.0)。
- A组客观缓解率19.5%(95%CI 8.8-34.9),B组16.1%(95%CI 5.5-33.7)。
- A组6个月临床获益率56.1%(95%CI 39.7-71.5),B组61.3%(95%CI 42.2-78.2)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fluoropyrimidines are commonly used in the treatment of metastatic breast cancer (MBC), and trifluridine/tipiracil (FTD/TPI) has shown activity in patients with colorectal and gastric cancers despite prior exposure to fluoropyrimidines. We investigate the role of FTD/TPI in patients with MBC with or without prior fluoropyridines in a single-arm phase II study. METHODS: Patients with MBC were enroled first into a run-in dose confirmation phase, followed by two parallel cohorts including patients with (Cohort A) and without (Cohort B) prior exposure to fluoropyrimidines, where they were treated with FTD/TPI. Primary objectives for each cohort included determination of progression-free survival (PFS), and secondary objectives included determination of objective response rates (ORR), safety, and tolerability. RESULTS: Seventy-four patients (42 Cohort A, 32 Cohort B) were enroled, all of whom were evaluable for toxicity and survival, with 72 evaluable for response. Median PFS was 5.7 months (95% confidence interval 3.8-8.3) and 9.4 months (95% CI 5.5-14.0) respectively in Cohorts A and B. Responses were observed regardless of prior exposure to fluoropyrimidines, with ORR of 19.5% (95% CI 8.8-34.9) and 16.1% (95% CI 5.5-33.7) in Cohorts A and B, and 6-month clinical benefit rates of 56.1% (95% CI 39.7-71.5) and 61.3% (95% CI 42.2-78.2) respectively. The safety profile was consistent with known toxicities of FTD/TPI, including neutropenia, fatigue, nausea, and anorexia, mitigated with dose modifications. CONCLUSION: FTD/TPI showed promising antitumour activity with manageable toxicity and is a clinically valid option in patients with MBC.
引用
- Lim JSJ, Ow SGW, Wong ALA, et al. Phase II study of trifluridine/tipiracil in metastatic breast cancers with or without prior exposure to fluoropyrimidines. Eur J Cancer. 2023. PMID: 37717281. doi:10.1016/j.ejca.2023.113311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。